1. Introduction {#sec1-cells-08-01027}
===============

HIV encodes pathogenic proteins, such as gp120, Nef, and Tat, that modulate cellular architecture and behavior. Such modulations are implicated in HIV-induced pathological processes, including immune activation that persist during combination antiretroviral therapy (cART) and contribute to serious non-AIDS events. Although cART has dramatically reduced HIV/AIDS-related pathologies and mortality \[[@B1-cells-08-01027]\], use of illicit substances (mostly psychostimulants) is a major barrier to combating the HIV pandemic \[[@B2-cells-08-01027],[@B3-cells-08-01027],[@B4-cells-08-01027],[@B5-cells-08-01027]\]. Psychostimulants such as cocaine have been linked to exacerbated HIV disease progression and HIV-associated disorders \[[@B6-cells-08-01027],[@B7-cells-08-01027],[@B8-cells-08-01027],[@B9-cells-08-01027],[@B10-cells-08-01027],[@B11-cells-08-01027],[@B12-cells-08-01027],[@B13-cells-08-01027]\]. In addition to its ability to promote risky behavior \[[@B14-cells-08-01027]\], cocaine impairs antiviral mechanisms \[[@B8-cells-08-01027],[@B15-cells-08-01027]\], thus increasing the risk of HIV acquisition. The combination of behavioral alteration and psychostimulant-mediated impairment of antiviral mechanisms continues to be a major obstacle in combating the global HIV/AIDS pandemic. The risk of exacerbated HIV disease progression and/or HIV-associated disorders among those who use psychostimulants and who are also infected with HIV is present in those adherent to cART \[[@B16-cells-08-01027],[@B17-cells-08-01027],[@B18-cells-08-01027]\].

Aside from the brain, peripheral tissues, including lymphocytes, monocytes, and the male urogenital organs, are responsive to psychostimulants due to the presence of dopamine transporters (DAT) and dopamine receptors (DR) \[[@B19-cells-08-01027],[@B20-cells-08-01027],[@B21-cells-08-01027]\]. In particular, DRD1 and DRD2 are expressed in male genital tissues such as the testis \[[@B22-cells-08-01027]\] and cocaine induces ultrastructural changes in the testis \[[@B23-cells-08-01027]\] and negatively affects testicular physiology as well as spermatogenic processes \[[@B23-cells-08-01027],[@B24-cells-08-01027]\]. Similar to its function in the central nervous system, the function of dopamine in myeloid cells is mediated primarily by DRs, which are expressed in human monocytes and macrophages \[[@B25-cells-08-01027],[@B26-cells-08-01027],[@B27-cells-08-01027]\]. Myeloid cell DRs are functional and have been implicated in HIV infection and substance use disorders \[[@B28-cells-08-01027]\]. Although peripheral cells have been linked to increased viral replication in the presence of psychostimulants \[[@B29-cells-08-01027],[@B30-cells-08-01027]\], how HIV and/or psychostimulants alter monocyte function is not completely understood.

Recently, acellular mechanisms regulating host functions have been discovered to occur through extracellular vesicles, in particular, exosomes, which are conveyors of bio-information \[[@B31-cells-08-01027],[@B32-cells-08-01027],[@B33-cells-08-01027]\]. Exosomes have been implicated in the modulation of immune responses \[[@B34-cells-08-01027],[@B35-cells-08-01027]\] and microbial pathogenesis, including HIV infection \[[@B36-cells-08-01027],[@B37-cells-08-01027],[@B38-cells-08-01027],[@B39-cells-08-01027],[@B40-cells-08-01027],[@B41-cells-08-01027],[@B42-cells-08-01027],[@B43-cells-08-01027],[@B44-cells-08-01027],[@B45-cells-08-01027]\]. Other biological processes, such as extracellular matrix (ECM) reorganization, epithelial barrier regulation, inflammatory cell recruitment, microglial migration \[[@B46-cells-08-01027]\], and regulation of HIV transcription \[[@B44-cells-08-01027]\], have been associated with exosomes \[[@B47-cells-08-01027]\]. Given that exosomes are released by various cell types into all body fluids \[[@B35-cells-08-01027],[@B36-cells-08-01027],[@B48-cells-08-01027],[@B49-cells-08-01027],[@B50-cells-08-01027],[@B51-cells-08-01027],[@B52-cells-08-01027],[@B53-cells-08-01027]\], it is likely that HIV infection and/or psychostimulant-mediated effects on peripheral tissues may be imprinted in exosomes and that such exosomes may reprogram host gene expression and function. In a recent study, we showed that SEs from HIV-uninfected donors who do not use psychostimulants selectively modifies HIV-induced activation of host transcription factors \[[@B44-cells-08-01027]\].

In the present study, our goal was to evaluate the effect of HIV infection, psychostimulant use, and co-occurring HIV/psychostimulant use on SE-mediated regulation of monocyte function. We used monocytes as a model because monocytes are present in nearly every tissue, including the brain that has little or no T cell colonization. Moreover, monocytes differentiate into HIV target cells---dendritic cells and macrophages. Finally, monocytes are the first cells recruited to sites of inflammation, are one of the immune cell types present in semen \[[@B54-cells-08-01027],[@B55-cells-08-01027]\], and are important target cells for mucosal HIV transmission \[[@B56-cells-08-01027]\], as well as HIV-associated neurocognitive disorders \[[@B57-cells-08-01027]\].

2. Materials and Methods {#sec2-cells-08-01027}
========================

2.1. Ethics {#sec2dot1-cells-08-01027}
-----------

This study involves the use of existing human specimens (semen) and, therefore, is not human subjects' research. De-identified semen samples were obtained from participants in the Multicenter AIDS Cohort Study (MACS), a prospective cohort study of the natural history of HIV infection in men who have sex with men which was initiated in 1984 in 4 US sites and obtained semen samples from study participants semiannually from 1984 to 1987. The semen samples were stored at −80 °C until analysis in the present study. The participants included HIV− and HIV+ men who, at the time of collection, reported using or not using illicit substances. Studies were conducted according to University regulations approved by The University of Iowa and Stony Brook University Institutional Review Boards (IRB \# 201608703). HIV-1-negative donors had no history of HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) infections. HIV-1-infected donors were ART-naive.

2.2. Semen Samples {#sec2dot2-cells-08-01027}
------------------

A total of 64 samples from four clinical groups (HIV-uninfected and not illicit substance users, HIV−Drug−; HIV-uninfected and self-reported illicit substance users, HIV-Drug+; HIV-infected and not illicit substance users, HIV+Drug−; and HIV-infected and self-reported use of illicit substances, HIV+Drug+). A participant was classified as an illicit substance user only if they reported using cocaine (taken by any route); in other words, if a participant reported using other substances without cocaine, they were excluded ([Table 1](#cells-08-01027-t001){ref-type="table"}). Sixteen participants in each group were analyzed. The samples were received frozen on dry ice from the MACS. The samples were collected between 1984 and 1987, and participants were between 20 and 65 years old.

2.3. Cells {#sec2dot3-cells-08-01027}
----------

U937 monocytic cells were obtained from the American Type Culture Collection (ATCC) and maintained in complete Roswell Park Memorial Institute (RPMI) media (Corning, Thermofisher, Grand Island, NY, USA). HIV-1 LAV-infected HeLa CD4+ cells from which HIV secretome was collected were obtained from the National Institutes of Health (NIH) Aids Reagent Program and maintained in complete Dulbecco's Modified Eagle Medium (DMEM) media. RPMI and DMEM media were supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Flowery Branch, GA, USA) that was exosome-depleted by ultracentrifugation (100,000× *g*, 2 h, 4 °C), 1% Penicillin-streptomycin (Thermofisher, Grand Island, NY, USA), 1 µg/mL Amphotericin B (Thermofisher, Grand Island, NY, USA), 2 mM sodium pyruvate (Corning, Corning, NY, USA), 1% of glutamate (Thermofisher, Grand Island, NY, USA), and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (Fisher Biotech, Fair Lawn, NJ, USA) at pH 8. NucBlue™ Live ReadyProbes™ reagent was purchased from EasyProbes (Thermofisher, Grand Island, NY, USA). Cell Viability Imaging Kit (Blue/Green) was obtained from Genecopoeia (Rockville, MD, USA), and Type I collagen was purchased from Corning (Corning, NY, USA).

2.4. Isolation of Exosomes {#sec2dot4-cells-08-01027}
--------------------------

64 semen samples from four clinical groups (n = 16/group) were liquefied at room temperature for 30 min and subsequently centrifuged at 10,000× *g* for 30 min to remove cellular debris and large vesicles. Clarified seminal plasmas were transferred to new tubes. For Nano Tracking Analysis (NTA) experiments, six pools of samples in each group, each pool from 2 participants (100 µL/sample), were used. Samples were pooled to obtain sufficient volume needed for efficient separation and analysis. For the rest of the experiments, 4 pooled samples (n = 16, 50 µL/sample) per clinical group were used. Exosomes were purified by size exclusion chromatography (SEC), where clarified seminal plasma was loaded onto Sephadex G-50 fine beads (GE-Healthcare, Pittsburgh, PA, USA) packed in a 22 cm × 1 cm Econo-column (Bio-Rad, Hercules, CA, USA). Elution was achieved by gravity using Phosphate Buffered Saline (PBS, Corning, NY, USA). Fractions of 200 µL were collected, and elution profiles were determined by absorbance measurements at 280 nm and 600 nm. The first peak which corresponds to semen exosomes (SE) was collected, and the protein content was measured by the Bradford Assay (Bio-Rad, Hercules, CA, USA). Of note, HIV could not be efficiently separated from semen exosomes using the Optiprep (Iodixanol)-based density gradient centrifugation method. While a good gradient prior to centrifugation was obtained, a satisfactory purification was not achieved due to the fact that the gold-standard exosomal marker AChE, as well as the exosomal markers CD9, CD63, and HSP70, along with the viral protein reverse transcriptase (RT) were found across the gradients. This is not surprising since HIV and exosomes overlap in size, density, and charge, and HIV is known to incorporate exosomal markers such as CD9, CD81 \[[@B58-cells-08-01027]\], and CD63 \[[@B59-cells-08-01027]\], while exosomes in turn also contain viral proteins \[[@B60-cells-08-01027]\] and RNA \[[@B61-cells-08-01027]\]. Immunocapture purification could not be used either because this mechanism depends on the use of antibodies against either host or viral proteins which are present in exosomes and HIV. Moreover, the "release" mechanism of exosomes trapped on the antibody-bead complex was inefficient. Thus, the inclusion of exosomal proteins in HIV and HIV proteins in exosomes hindered separation of these vesicles but also highlighted the need to assess the vesicles in their near-native state to understand their effect on host cells.

2.5. Nanoparticle Tracking Analysis (NTA) {#sec2dot5-cells-08-01027}
-----------------------------------------

Exosome size and concentration were measured by NTA using ZetaView PMX 110 (Particle Metrix, Mebane, NC, USA) and the corresponding software ZetaView v8.04.02. Samples were diluted appropriately in ultrapure water and measured under the same settings (temperature 25 °C, sensitivity 92, shutter speed 70, and frame rate 30 fps). Data acquisition for size and concentration was performed in triplicate measurements, and each replicate corresponded to 11 positions with two cycles of reading at each position. The system was aligned and calibrated with 102-nm polystyrene standard beads. After automated analysis of the 11 positions and removal of any outlier position, the median number (X50) was used to report the particle size. The measured concentration was normalized to the volume of plasma and reported in particles/mL of seminal plasma. For zeta potential, measurements were performed in ultrapure water (pH 5.8) and data were acquired in quintuplicate. Each replicate corresponded to two cycles of reading.

2.6. Transmission Electron Microscopy (TEM) {#sec2dot6-cells-08-01027}
-------------------------------------------

Microscopic analysis of exosome samples was performed as previously described \[[@B36-cells-08-01027],[@B38-cells-08-01027]\]: 200 µL of purified SE were buffer exchanged with Tris buffer (pH = 7.5, 1 M) and concentrated through a 0.5-mL centrifugal filter (10,000 NMWL) into 50 µL; 10 µL of concentrated SE was applied on to carbon-coated copper grids (Pellco Easiglow, 0.2 mpar, 30 mA, 40 s, negative) and allowed to sit for 30 s. Excess samples were removed with filter paper. The grids were washed with distilled deionized water (ddH~2~O) twice, stained with 0.7% Uranyl Formate solution for 20 s, and then allowed to air dry. Images were viewed and collected using a FEI Tecnai12 BioTwinG 2 electron microscope. The samples were captured with an AMT XR-60 CCD Digital Camera system. The size of particles from TEM images were quantified by ImageJ.

Microscopic analysis of exosome samples was performed as previously described \[[@B36-cells-08-01027],[@B38-cells-08-01027]\]: 200 µL of purified SE were buffer exchanged with Tris buffer (pH = 7.5, 1 M) and concentrated through a 0.5-mL centrifugal filter (10,000 NMWL) into 50 µL; 10 µL of concentrated SE was applied on to carbon-coated copper grids (Pellco Easiglow, 0.2 mpar, 30 mA, 40 s, negative) and allowed to sit for 30 s. Excess samples were removed with filter paper. The grids were washed with distilled deionized water (ddH~2~O) twice, stained with 0.7% Uranyl Formate solution for 20 s, and then allowed to air dry. Images were viewed and collected using a FEI Tecnai12 BioTwinG 2 electron microscope. The samples were captured with an AMT XR-60 CCD Digital Camera system. The size of particles from TEM images were quantified by ImageJ.

2.7. Reverse Transcriptase (RT) Assay {#sec2dot7-cells-08-01027}
-------------------------------------

HIV RT activity was determined with an EnzCheck Reverse Transcriptase Assay kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Briefly, 30 µg (\~6 × 10^9^ particles) of purified SE (6 pools of 2 donors each for HIV+Drug− and HIV+Drug+ groups) were lysed with 6 µL Triton X-100 in a total volume of 50 µL per well, to which 20 µL of poly(A)-oligo(dT) in a polymerization buffer were added. Assay was performed in a 96-well black plate in triplicates. An equivalent volume of PBS was used as the negative control. RT standard curve was prepared with serial dilution (0, 0.625, 1.25, 2.5, and 5 µg/mL) of Murine Leukemia Virus (MLV) recombinant RT.

2.8. ELISA Assays {#sec2dot8-cells-08-01027}
-----------------

HIV p24 ELISA (Xpressbio, Frederick, MD, USA) and cocaine ELISA (Abnova, Taipei, Taiwan, China) were conducted by following the manufacturers' protocols. Briefly, for HIV p24 ELISA, a total of 30 µg purified SE (\~6 × 10^9^ particles) from HIV+ groups were tested in 6 pools of 2 donors each. An equivalent volume of PBS was used as the negative control. The same procedure was adopted for cocaine metabolite ELISA, with Drug+ groups being tested (6 pools of 2 donors each per group) in triplicate. The detection limit of the ELISA kit for HIV p24 and cocaine were 1.7 pg/mL and 1 ng/mL, respectively.

2.9. RNA Purification {#sec2dot9-cells-08-01027}
---------------------

Collagen coating of tissue culture plates was described previously \[[@B62-cells-08-01027]\]. Briefly, 6-well tissue culture plates were pre-coated with 50 µg/mL of collagen for 2 h at 37 °C, after which 1 mL of 2 mg/mL bovine serum albumin (BSA, Research Products International, Mount Prospect, IL, USA) was added to block nonspecific sites. Two million U937 cells treated with vehicle (PBS) or 100 µg/mL of SE from each of the four clinical groups were plated and incubated for 18 h at 37 °C and 5% CO~2~. Each treatment included three replicates. Subsequently, total RNA was extracted using the miRNeasy Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's protocol. An on-column DNAse digestion step (RNase-Free DNase set, Qiagen) was added after the first buffer wash step. The yield, quality, and size distribution of RNA isolated from the cells were determined using the Bioanalyzer instrument (Agilent, Santa Clara, CA, USA). Six hundred ng of the RNA from each treatment group was applied to an RNA Nano Chip, and the RNA profiles were detected and analyzed on the Agilent 2100 Bioanalyzer with 2100 Bioanalyzer expert software (v B.02.08.S1648 (SR 1)). The electropherogram traces and "gel-like" images were exported from the instrument's software and presented in [Supplementary Figure S1](#app1-cells-08-01027){ref-type="app"}. Isolated RNA was used for microarray analysis or for cDNA synthesis and subsequent real-time quantitative PCR (RT-qPCR) analysis.

2.10. Microarray Analysis, Data Mining, and Data Visualization {#sec2dot10-cells-08-01027}
--------------------------------------------------------------

150 ng of total RNA was prepared for microarray analysis using the GeneChip™ WT PLUS Reagent Kit (Applied Biosystems, Foster City, CA) according to manufacturer's protocol. The samples were hybridized (16 h) to Clariom™ S Human Arrays (Applied Biosystems, Foster City, CA) in a GeneChip™ Hybridization Oven 645 (Applied Biosystems™). The arrays were washed and stained using the GeneChip™ Hybridization, Wash and Stain Kit (Applied Biosystems, Foster City, CA) in a GeneChip™ Fluidics Station 450 according to manufacturer's protocol. The arrays were scanned in a GeneChip™ Scanner 3000 7G (Applied Biosystems, Foster City, CA). Quality control and initial analysis, including scatterplots of differentially expressed genes (DEGs), Venn analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, were performed using Transcriptome Analysis Console (TAC) v 4.0.0.25 (Applied Biosystems, Foster City, CA). Clustered heatmaps were plotted using heatmapper \[[@B63-cells-08-01027]\] ([www.heatmapper.ca](www.heatmapper.ca)), with the average linkage method and Euclidean distance measurement method. The lists of SE, SE-Drug, and SE-HIV DEGs that were obtained from a TAC analysis were subjected to data mining in a Web-based Gene Set Analysis Toolkit (WebGestalt \[[@B64-cells-08-01027]\], [www.webgestalt.org](www.webgestalt.org)), from which biological process and molecular function and cellular component gene ontology (GO) terms were obtained.

2.11. Primer Design and Real-Time Quantitative PCR (RT-qPCR) Data Validation {#sec2dot11-cells-08-01027}
----------------------------------------------------------------------------

Primers were designed using the Thermofisher oligoperfect program (<https://www.thermofisher.com/us/en/home/life-science/oligonucleotides-primers-probes-genes/custom-dna-oligos/oligo-design-tools/oligoperfect.html>). Primers were in silico validated using the University of California, Santa Cruz (UCSC) in silico-pcr program (<http://mgc.ucsc.edu/cgi-bin/hgPcr>). The designed primers are listed in [Table 2](#cells-08-01027-t002){ref-type="table"}. Five µg total RNA was used for cDNA synthesis using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Thermofisher). The cDNA was stored at −20 °C until use. The thermal cycler program and expression calculation was setup in a 7500 FAST real-time PCR system (Applied Biosystems, Thermofisher), and the fold change in gene expression was calculated using the standard ∆∆CT method.

2.12. Collagen Adhesion Assay {#sec2dot12-cells-08-01027}
-----------------------------

Flat-bottom 96-well plate were pre-coated with 50 µL of 50 µg/mL of Type I collagen (Corning, Corning, NY, USA) for 2 h at 37 °C; 40 µL of 2 mg/mL Bovine Serum Albumin (BSA) was used to block the nonspecific sites. Incoming U937 cells (10,000 cells/well) treated with 100 µg/mL of SE or with equivalent volume of vehicle (PBS control) were added to the pre-coated wells and allowed to adhere for 18 h at 37 °C. Non-adhered cells were gently washed off with PBS three times. The adhered cells were labeled with NucBlue™ for 20 min at room temperature, and the wells were imaged (4× objective) in their entirety in the DAPI channel (360 nm/460 nm excitation/emission) using a Lionheart FX Automated Microscope (BioTek, Winooski, VT, USA). The captured images were then stitched, and the cell numbers were calculated using Gen5 ImagePrime. Values were represented as the number of total adhered cells in each well. Each treatment included four repeated wells.

2.13. Evaluation of Cell Viability and Proliferation {#sec2dot13-cells-08-01027}
----------------------------------------------------

A total of 10,000 U937 cells per well were seeded in a collagen-coated 96-well plate with 100 µg/mL of SE or equivalent volume of PBS for 18 h at 37 °C. All cells were collected after treatment and tested for viability by the Trypan Blue (Life Technologies, Carlsbad, CA, USA) exclusion and Live/Dead Cell Stain (Cell Viability Imaging Kit, GeneCopoeia, Rockville, MD, USA) methods. Cell proliferation was determined by counting the total number of live cells. The experiments were repeated 3 times, and each experiment included three replicates.

2.14. Immunofluorescence-Based Analysis of Cytoskeletal Changes and Focal Adhesion {#sec2dot14-cells-08-01027}
----------------------------------------------------------------------------------

U937 cells were plated (10,000 cells/well) on a 96-well glass bottom dish (Cellvis, Mountain View, CA, USA) coated with Type I collagen and treated with 100 µg/mL of respective SE. The plate was centrifuged at 200× *g* for 8 min to facilitate cellular adherence to the bottom of the well and incubated at 37 °C for 18 h. Following incubation, cells were washed with PBS and fixed with 4% paraformaldehyde (PFA) in PBS for 15 min. Cells were then permeabilized by incubation in 0.1% TritonX-100 for 10 min. AlexaFluor 594 Phalloidin (Thermofisher, Grand Island, NY, USA) and Alexa Fluor 488 Vinculin (Thermofisher, Grand Island, NY, USA) were applied in a 1:40 dilution for 1 h, followed by a 5-min DAPI stain. Images were acquired using a Lionheart FX Automated Microscope (Biotek, Winooski, VT, USA). Representative 10× and 60× images were acquired manually for five fields of view per well. Image procession was performed using Gen5 ImagePrime. Quantification of cellular size, area, and circularity was performed by Gen5 ImagePrime via masking of phalloidin. A circularity metric was created by inputting the equation $C = 4\pi A/P^{2}$, where $C$ is the circularity, $A$ is the area of the cell, and $P$ is the perimeter of the cell (<https://imagej.nih.gov/ij/plugins/circularity.html>).

2.15. Colocalization Analysis {#sec2dot15-cells-08-01027}
-----------------------------

60× fluorescent images of U937 cells treated with vehicle or SE (100 µg/mL) and stained with Alexa Fluor 594 Phalloidin and Alexa Fluor 488 Vinculin captured on a Lionheart FX Automated Microscope were imported into ImageJ (<http://imagej.nih.gov/>) for colocalization analysis. An open source ImageJ plugin "EzColocalization" (<http://sites.imagej.net/EzColocalization/plugins/>) was used to quantify colocalization of actin (phalloidin) and vinculin at regions of cell--cell contact and membrane protrusions. Regions of interests (ROIs) were selected via an ROI manager. Using EzColocalization, Pearson correlation coefficient (PCC) and Threshold overlap score (TOS, linear) quantifications were performed for 7 representative fields of view per SE treatment and vehicle. PCC and TOS (linear) values for each ROI were exported into GraphPad Prism for further analysis. One-way ANOVA was performed to determine the significance of SE treatment relative to the vehicle. Colocalization heatmaps were generated using the ImageJ plugin "Colocalization Colormap" (<https://sites.google.com/site/colocalizationcolormap/home>).

2.16. Chemotaxis {#sec2dot16-cells-08-01027}
----------------

Migration assays were conducted in a 10-well chemotaxis chamber (Neuroprobe Inc., Gaithersburg, MD, USA). Basal chambers were filled with media containing 0% FBS (serum-free), 30% FBS, or conditioned media from HIV-1 LAV-infected HeLa CD4+ cells (HIV secretome). A polycarbonate polyvinylpyrrolidone-free filter with a pore size of 5 µm was then placed over the lower chambers, and 285 µL of U937 cell suspensions (500,000 cells per well) that were pretreated for 24 h with either vehicle or 100 µg/mL SE from the 4 clinical groups in equal volumes of serum-free media were placed on the filter. The chambers were incubated for an additional 20 h at 37 °C in a 5% CO~2~ incubator. The apical chamber cells were carefully harvested, membranes were thoroughly rinsed, and basal chamber cells were harvested by piercing the membrane in the basal chamber. Cell suspensions were mixed with Trypan Blue dye, and total cell numbers and viability were quantified via hemocytometer counting.

2.17. Gelatin and Casein Zymography {#sec2dot17-cells-08-01027}
-----------------------------------

After the 24 h serum starvation for migration assays, the conditioned media was harvested on ice. Following a 2000× *g* centrifuge step for 10 min, the media was mixed with a 4× Laemmli sample buffer (Bio-rad, Hercules, CA, USA) with the absence of boiling or 2-mercaptoethanol. Ten percent SDS-PAGE gels (0.75 mm thick) containing 0.1% gelatin in the resolving gel were prepared. Equal volumes of samples were loaded into the lanes, and electrophoresis was performed (Mini-PROTEAN Bio-Rad). Gels were removed from their cassettes, rinsed in distilled water, and incubated with a 1× Zymogram Renaturation Buffer (Bio-Rad) for 30 min with gentle agitation to remove SDS and to renature the proteins. Gels were then transferred to a 1× Zymogram Development Buffer (Bio-rad) for 30 min at room temperature, followed by replacement with fresh development buffer and incubated for 24 h at 37 °C to allow proteolytic digestion of the gelatin substrate. Gels were then rinsed with distilled water and stained with Coomassie blue for 30 min. Destaining was carried out with 50% methanol and 10% acetic for 1 h. Zones of gelatin degradation were imaged using an Odyssey CLx Imaging system (LI-COR Biosciences, Lincoln, NE, USA). The area of destained bands (zones of gelatin degradation) was then measured with ImageJ analyzing software and normalized to the value of vehicle treated samples. B-casein zymography was performed as described for gelatin zymography, aside from the inclusion of a 40 mA gel pre-running step performed prior to sample loading.

2.18. Statistical Analysis {#sec2dot18-cells-08-01027}
--------------------------

The expression analysis settings for the microarray analysis were as follows: Gene-Level Fold Change \< −2 or \> 2, Gene-Level *p*-Value \< 0.05, and ebayes ANOVA Method. The matrix correlation analysis was performed using GraphPad Prism software (v 8.1.2). Graphpad Prism was also used to plot all the graphs and to determine the statistical significance in this study. For a two-group comparison, unpaired t-test with Welch's correction was used to determine the differences between the groups. For a four-group comparison, ordinary one-way ANOVA test with Dunnett's correction was used in this study to determine the differences between SE groups as compared to HIV−Drug−. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.005, \*\*\*\* *p* \< 0.001, and ns, nonsignificant.

2.19. Data Availability {#sec2dot19-cells-08-01027}
-----------------------

The authors declare that all data supporting the findings of this study are available within the article. Microarray data have been deposited in the Gene Expression Omnibus (GEO) under accession code GSE129506.

3. Results {#sec3-cells-08-01027}
==========

3.1. Biophysical Characterization of SE from Study Participants {#sec3dot1-cells-08-01027}
---------------------------------------------------------------

Ultraviolet--visible spectroscopy (UV--Vis) analysis of SE profiles indicated that the fractions eluted in the void peak were enriched in vesicles, whereas the vesicle-free proteins eluted in the latter peak ([Figure 1](#cells-08-01027-f001){ref-type="fig"}A). Comparison of the profiles from the different clinical groups (n = 6) showed subtle differences in the height of the peaks ([Figure 1](#cells-08-01027-f001){ref-type="fig"}A). The first peak, designated as SE, was collected and analyzed for protein concentration. No significant differences were observed in each of the SEs with protein concentrations ranging from 6.86 to 8.55 mg/mL of plasma ([Figure 1](#cells-08-01027-f001){ref-type="fig"}B). NTA revealed subtle differences in SE size and concentration ([Figure 1](#cells-08-01027-f001){ref-type="fig"}C) while the mean size of SE from HIV+Drug− was significantly different from the other groups ([Figure 1](#cells-08-01027-f001){ref-type="fig"}D), the mean concentration was not different ([Figure 1](#cells-08-01027-f001){ref-type="fig"}E). Since the electrical properties of the exosomal surface measured as ζ-potential is determined by the surface molecules on exosome membranes, we examined the effect of HIV infection and psychostimulant use on the ζ-potential of SE. Mean ζ-potential of HIV−Drug−, HIV−Drug+, and HIV+Drug− SE were not significantly different. In contrast, the ζ-potential of SE from HIV+Drug+ participants were significantly different from the HIV−Drug− SE ([Figure 1](#cells-08-01027-f001){ref-type="fig"}F). TEM-based analysis showed no significant differences in SE morphology and size ([Figure 1](#cells-08-01027-f001){ref-type="fig"}G,H).

3.2. HIV Proteins and Cocaine Metabolite (Benzoylecgonine) Are Associated with SE {#sec3dot2-cells-08-01027}
---------------------------------------------------------------------------------

RT assay and HIV p24 ELISA were used to assess the level of viral proteins associated with SE. The results showed mean values of 9.03 and 11.49 RT unit/mL for the HIV+Drug− and HIV+Drug+ groups, respectively ([Figure 1](#cells-08-01027-f001){ref-type="fig"}I), whereas p24 mean values were 4.17 and 4.4 pg/mL for the HIV+Drug− and HIV+Drug+ groups, respectively ([Figure 1](#cells-08-01027-f001){ref-type="fig"}J). Furthermore, the ELISA assay showed that detectable levels of cocaine metabolite benzoylecgonine is associated with SE, albeit below the assay detection limit of 1 ng/mL. Although the reasons for low levels of HIV proteins and benzoylecgonine in SE are unknown, it could be that the proteins and metabolites may be low in SE or that they are degraded, given the age of the seminal samples (\~32 years) and the short half-life of benzoylecgonine, which is about 24 h for a single dose and a maximum of 10 days for chronic users \[[@B65-cells-08-01027]\]. It is also possible that SE do not carry this specific cocaine metabolite---benzoylecgonine. However, we were unable to assess other viral proteins and cocaine metabolites due to limited semen samples. Our data suggest that both HIV proteins and cocaine metabolite may be associated with SE.

3.3. The effect of SE Stimulation on Gene Expression Signature of Collagen-Cultured Monocytes {#sec3dot3-cells-08-01027}
---------------------------------------------------------------------------------------------

Since HIV infection and psychostimulant use did not significantly change the biophysical properties of SE, we examined the effect of SE from the different clinical backgrounds on the gene expression profile of monocytes cultured atop collagen as the substrate. We selected collagen as a relevant ECM because collagen is the most abundant matrix protein and HIV stimulates local production of collagen \[[@B66-cells-08-01027]\], which provides activating signals to myeloid cells, drives sustained inflammation, and alters the architecture of lymphoid tissues \[[@B67-cells-08-01027],[@B68-cells-08-01027]\]. [Figure 2](#cells-08-01027-f002){ref-type="fig"}A shows the distribution of all genes stimulated by the different SE in comparison to vehicle-treated cells. The correlation matrix, including all genes (21448) within the five treatment groups regardless of significance, shows that, in general, HIV−Drug− SE have minimal effect on the gene expression pattern of monocytes. However, psychostimulant use and/or HIV infection altered monocyte gene expression pattern ([Figure 2](#cells-08-01027-f002){ref-type="fig"}B). Since monocytes express DRs which mediate cellular response to dopamine \[[@B69-cells-08-01027]\], we analyzed microarray data for levels of DR following treatment with the different SE. The results showed that monocytes express mRNA of DR variants ([Figure 2](#cells-08-01027-f002){ref-type="fig"}C), although none of the SE significantly altered DR mRNA levels.

The effect of SE stimulation on monocytes gene expression profile was further delineated by identifying the differentially expressed genes (DEGs) shown in [Table 3](#cells-08-01027-t003){ref-type="table"}. Two-way Venn-filtration identified genes commonly altered by SE, regardless of the clinical group ([Figure 2](#cells-08-01027-f002){ref-type="fig"}D). This analysis showed an overlap of 30 SE DEGs. Hierarchical clustered heatmap ([Figure 2](#cells-08-01027-f002){ref-type="fig"}E) and a bar graph of fold change analysis ([Figure 2](#cells-08-01027-f002){ref-type="fig"}F) was used to visualize the relationship between the genes, the direction of gene regulation, and the type of SE that elicited the regulation. In comparison to steady state levels of gene expression observed in vehicle-treated cells, 17 genes were upregulated by SE while 13 genes were suppressed by SE ([Figure 2](#cells-08-01027-f002){ref-type="fig"}F). These results revealed specific gene expression signatures imprinted by SE from different clinical backgrounds. Among these DEGs are MMP1 and MMP19, which are proteins linked to the breakdown of extracellular matrix (ECM) in normal physiological (embryonic development, reproduction, and tissue remodeling) \[[@B70-cells-08-01027]\] and disease processes (arthritis, cancer metastasis, and HIV pathogenesis) \[[@B71-cells-08-01027],[@B72-cells-08-01027]\]. In addition, the pro-inflammatory proteins CCL3, S100A8, and C5aR1 \[[@B73-cells-08-01027],[@B74-cells-08-01027],[@B75-cells-08-01027]\]; inflammatory regulators FPR1, FPR3, and TNFAIP6 \[[@B76-cells-08-01027],[@B77-cells-08-01027]\]; cell proliferation, differentiation, and transformation regulatory proteins FOSB and FOS \[[@B78-cells-08-01027]\]; and transcription factors EGR1 and EGR3 \[[@B79-cells-08-01027]\] were also among the DEGs dysregulated by the different SEs.

3.4. SE from Psychostimulant Users or HIV-Infected Participants Dysregulate Monocyte Gene Expression {#sec3dot4-cells-08-01027}
----------------------------------------------------------------------------------------------------

Two-way Venn-filtration was used to identify DEGs in cells treated with SE from HIV−Drug+ and HIV+Drug+ participants designated as SE-Drug DEGs ([Figure 3](#cells-08-01027-f003){ref-type="fig"}A). Our analysis revealed that SE-Drug differentially regulated 52 genes, which is more than the 30 SE DEGs ([Figure 2](#cells-08-01027-f002){ref-type="fig"}D--F). The relationship between the different genes induced by SE-Drug can be visualized using a hierarchical clustering heatmap ([Figure 3](#cells-08-01027-f003){ref-type="fig"}B). [Figure 3](#cells-08-01027-f003){ref-type="fig"}C shows individual genes within each of the SE-Drug DEGs and their expression patterns. A total of 9 genes were upregulated by SE-Drug while 43 genes were downregulated. Noteworthily, among the upregulated SE-Drug DEGs was collagen alpha-1(XVI) chain (COL16A1), known to be involved in inducing MMP9 secretion through AP-1 activation \[[@B80-cells-08-01027]\], in mediating cell attachment, in inducing integrin-mediated cellular reactions such as cell spreading and alterations in cell morphology \[[@B81-cells-08-01027],[@B82-cells-08-01027]\], and in promoting glioma cell adhesion \[[@B83-cells-08-01027]\] and invasion \[[@B84-cells-08-01027]\]. Conversely, HUS1 Checkpoint Clamp Component B (HUS1B), which overexpression has been shown to induce cell death \[[@B85-cells-08-01027]\], was potently suppressed by Drug-SE. We used a similar approach to characterize gene expression changes induced by SE from HIV+Drug− and HIV+Drug+ participants (SE-HIV). The analysis identified 149 (65 upregulated and 84 downregulated) SE-HIV DEGs ([Figure 3](#cells-08-01027-f003){ref-type="fig"}D), of which the hierarchical clustering ([Figure 3](#cells-08-01027-f003){ref-type="fig"}E) revealed subtle differences between the two SE-HIV (HIV+Drug− and HIV+Drug+) groups compared to vehicle control. Fold differences and direction of gene expression between the SE-HIV groups are shown in [Figure 3](#cells-08-01027-f003){ref-type="fig"}F. Among the 65 upregulated SE-HIV DEGs were inflammatory molecules, such as CCL4L1 and Resistin (RETN), transcription factors (RELB and MXD1), and antiviral molecules such as Interferon-induced antiviral RNA-binding protein (IFIT1) \[[@B86-cells-08-01027]\], whereas among the top downregulated SE-HIV DEGs was Tuberous Sclerosis 1 (TSC1), which is a tumor suppressor gene that maintains HIV-1 latency by negatively regulating the AKT-mTORC1 pathway \[[@B87-cells-08-01027]\].

3.5. Gene Ontology (GO) Analysis {#sec3dot5-cells-08-01027}
--------------------------------

We used GO enrichment analyses to predict the possible biological roles of the identified DEGs ([Figure 4](#cells-08-01027-f004){ref-type="fig"}A--F). [Table 4](#cells-08-01027-t004){ref-type="table"}, [Table 5](#cells-08-01027-t005){ref-type="table"} and [Table 6](#cells-08-01027-t006){ref-type="table"} summarize the top 10 GO Terms enriched in three ontologies---biological processes ([Figure 4](#cells-08-01027-f004){ref-type="fig"}A,C,E and [Table 4](#cells-08-01027-t004){ref-type="table"}), molecular function ([Figure 4](#cells-08-01027-f004){ref-type="fig"}B,D,F and [Table 5](#cells-08-01027-t005){ref-type="table"}), and cellular component ([Table 6](#cells-08-01027-t006){ref-type="table"}). Furthermore, [Table 7](#cells-08-01027-t007){ref-type="table"} listed the top 10 KEGG pathways identified by Webgestalt analysis. KEGG pathway by count, as determined by TAC software, identified focal adhesion as one of the top 10 common pathways in cells treated with SE from the four clinical groups ([Table 8](#cells-08-01027-t008){ref-type="table"}).

3.6. Validation of Microarray Data {#sec3dot6-cells-08-01027}
----------------------------------

A subset of DEGs linked to two ontology terms---biological processes and molecular functions ([Figure 4](#cells-08-01027-f004){ref-type="fig"}A--F, blue and red fonts)---were used for real-time quantitative PCR (RT-qPCR) validation using the primers shown in [Table 2](#cells-08-01027-t002){ref-type="table"}. The results show overall agreement between RT-qPCR and microarray results ([Figure 4](#cells-08-01027-f004){ref-type="fig"}G), with subtle variation that may be attributed to assay differences. This validation study confirms that many genes were indeed differentially regulated by SE and that HIV infection, psychostimulant use, and HIV/psychostimulant use have the ability to regulate SE function.

3.7. SE from HIV-Infected Participants Who Used Psychostimulants Enhanced Monocyte Adhesion to Collagen {#sec3dot7-cells-08-01027}
-------------------------------------------------------------------------------------------------------

Since cell adhesion molecule binding is a molecular function GO term in gene expression analysis and COL16A1 involved in cell adhesion \[[@B81-cells-08-01027],[@B82-cells-08-01027],[@B83-cells-08-01027]\] is upregulated by SE-Drug ([Figure 3](#cells-08-01027-f003){ref-type="fig"}C), we assessed the effect of SE on the adhesion of U937 monocytes to collagen. Monocyte adhesion occurred in untreated cells, with reduced adhesion when a serum-free medium was used. Compared to vehicle-treated cells, SE from all four clinical groups increased monocyte adhesion both in complete ([Figure 5](#cells-08-01027-f005){ref-type="fig"}A) and serum-free ([Figure 5](#cells-08-01027-f005){ref-type="fig"}B) media. However, adhesion of monocytes treated with HIV+Drug+ SE was the most enhanced. The increases in adhesion cannot be attributed to serum since similar increases were observed in serum-free conditions (compare [Figure 5](#cells-08-01027-f005){ref-type="fig"}A,B). Furthermore, the increase in the number of adherent cells cannot be attributed to cell death or cell proliferation since none of the SE had cytotoxic ([Figure 5](#cells-08-01027-f005){ref-type="fig"}C,D) or proliferative ([Figure 5](#cells-08-01027-f005){ref-type="fig"}E,F) effects on U937 cells under the same experimental conditions.

3.8. SE from HIV-Infected and Psychostimulant Users Induce Actin Reorganization {#sec3dot8-cells-08-01027}
-------------------------------------------------------------------------------

To further understand the effects of SE on monocyte adhesion to collagen, we examined cell morphology and cytoskeletal dynamics of SE-treated cells compared to vehicle-treatment. SE from different clinical groups induced distinct changes in cell morphology and actin organization in monocytes ([Figure 6](#cells-08-01027-f006){ref-type="fig"}A). When unstimulated or HIV−Drug− SE-treated monocytes were allowed to adhere to collagen-coated coverslips, the majority of cells maintained a cortical ring of actin filaments ([Figure 6](#cells-08-01027-f006){ref-type="fig"}A, columns 1 and 2). In the presence of SE-Drug and SE-HIV, monocytes displayed considerable degrees of spreading and polarization ([Figure 6](#cells-08-01027-f006){ref-type="fig"}A, columns 3 to 5) with actin localized to membrane ruffles and areas of cell-to-cell contacts ([Figure 6](#cells-08-01027-f006){ref-type="fig"}A, columns 3 to 5). SE-polarized cells displayed asymmetric morphology suggestive of cell migration, with cell periphery displaying membrane ruffles and filopodia-like structures ([Figure 6](#cells-08-01027-f006){ref-type="fig"}A). We measured the dynamics of SE on cell spreading by quantifying the cell size and cell area. Cells treated with vehicle had an average size of 14.74 µm, with a spread cell area of 172.48 μm^2^ ([Figure 6](#cells-08-01027-f006){ref-type="fig"}B,C). The size (14.58 μm) and area (170.63 μm^2^) of cells treated with HIV−Drug− SE were similar to vehicle-treated cells. At variance, HIV−Drug+, HIV+Drug−, and HIV+Drug+ SE significantly increased cell sizes to 16.65, 18.49, and 20.5 µm respectively, and cell areas to 221.33, 274.16, and 333.70 μm^2^ respectively ([Figure 6](#cells-08-01027-f006){ref-type="fig"}B,C). To further assess monocyte morphometrics, we traced the cell membrane ([Figure 6](#cells-08-01027-f006){ref-type="fig"}D) and determined monocyte circularity. Monocytes are circular cells, and the circularity of cells treated with vehicle was highest at 0.71, with 1 being a perfect circle. In contrast, average cell circularity increased to 0.76 in cells treated with HIV−Drug− SE. However, treatment of monocytes with HIV−Drug+, HIV+Drug−, or HIV+Drug+ SE decreased monocyte circularity to 0.65, 0.63, and 0.58 respectively ([Figure 6](#cells-08-01027-f006){ref-type="fig"}E). These data further support the induction of membrane ruffles and filopodia-like structures in monocytes treated with SE-Drug or SE-HIV and suggest that infection with HIV or use of psychostimulants alter the function of SE. Noteworthy is that filopodia and other thin membrane protrusions are sensitive to PFA fixation \[[@B88-cells-08-01027]\]. Since our cells were fixed, we may have underestimated the extent of membrane protrusions on the cells. Thus, studies of the effect of SE on monocyte morphometrics using unfixed living cells is warranted and not conducted in the present study due to limited semen specimens from all clinical groups. However, our data suggest that SE-Drug and SE-HIV induce monocytes to polarize.

3.9. SE from HIV Infected and Psychostimulant Users Enhance Monocyte Chemotaxis {#sec3dot9-cells-08-01027}
-------------------------------------------------------------------------------

Given the reported enhanced adhesion of monocytes to endothelial surfaces in the context of HIV infection \[[@B89-cells-08-01027],[@B90-cells-08-01027]\] and our observation that SE-Drug and SE-HIV modified monocyte cytoskeleton and exacerbated their adhesion to collagen, we sought to gain further insights into the effect of SE from psychostimulant users and HIV-infected subjects on monocyte motility. In general, while all SE induced chemotactic migration, HIV+Drug+ had the highest induction. In comparison to vehicle, HIV−Drug− SE modestly induced monocyte chemotaxis to HIV secretome, but chemotaxis was significantly higher in cells treated with SE from HIV+Drug− (20-fold increase), HIV−Drug+ (\~19-fold increase), and HIV+Drug+ (\~33-fold increase), in that order ([Figure 7](#cells-08-01027-f007){ref-type="fig"}A). The differences in chemotaxis is independent of cell viability ([Figure 7](#cells-08-01027-f007){ref-type="fig"}B), suggesting that HIV infection and psychostimulants use may reprogram SE to induce monocyte motility.

3.10. HIV Infection and Psychostimulant Use Enhanced Secretion of SE that Activated Matrix Metalloproteinases {#sec3dot10-cells-08-01027}
-------------------------------------------------------------------------------------------------------------

Various gelatinolytic degradative areas corresponding to active and pro MMP2 and MMP9, along with other MMP species were observed in secretomes of SE-treated cells compared to vehicle-treated cells ([Figure 7](#cells-08-01027-f007){ref-type="fig"}C). The highest gelatinolytic activity measured by the total degradative area was 3.4-fold compared to vehicle-treated cells, and this activity was observed in th secretomes of cells treated with HIV−Drug+ SE ([Figure 7](#cells-08-01027-f007){ref-type="fig"}D). Similarly, secretomes from SE-treated cells contain caseinolytic enzymes ([Figure 7](#cells-08-01027-f007){ref-type="fig"}E). For both gelatin and casein zymographs, the cleared bands indicate areas of enzymatic activities while the arrows/brackets indicate various MMP species based on the correspondence of their size (kDa) to known MMP sizes. Casein zymography is technically challenging and less sensitive than gelatin zymography (compare [Figure 7](#cells-08-01027-f007){ref-type="fig"}C,E). This is partly because of the migration pattern of casein which results in two clearly defined zones in the gel ([Figure 7](#cells-08-01027-f007){ref-type="fig"}E, less and excess casein), the lower part that contains excess casein and the upper part with less casein. This is problematic because some MMPs, such as the pro (\~28 kDa) and active (\~20 kDa) forms of MMP7, migrate near the casein-migration boundary and were difficult to distinguish. While gelatin zymography predominantly detects MMP2 and MMP9 activities, casein is a preferential substrate for MMP3, MMP7, MMP12, and MMP13 \[[@B91-cells-08-01027],[@B92-cells-08-01027],[@B93-cells-08-01027]\]. Quantitation of select caseinolytic degradative areas showed that HIV−Drug+ SE-treated cells produced increased amounts of high molecular weight caseinolytic complexes ([Figure 7](#cells-08-01027-f007){ref-type="fig"}F) with subtle differences in MMP7 ([Figure 7](#cells-08-01027-f007){ref-type="fig"}G). Collectively, these results provide evidence of SE-induced migration and ECM-modifying MMPs that degrade gelatin (denatured form of collagen) and β-casein. However, whether SE-mediated cell migration and activation of MMPs play a role in immune surveillance, viral pathogenesis, maintenance, and/or disruption of barrier integrity remains to be determined. It also remains to be determined what role, if any, SEs play in activating lipases and other proteases.

HIV infection and psychostimulant use promote secretion of SE that enhanced formation of focal adhesions and adherence junctions: Since formation of focal adhesion (FA) is integral to cell adhesion and migration, we examined the effects of SE on FA using the general adhesion proteins vinculin and F-actin, which form part of the cell's cytoskeleton. While vinculin localized to cell-to-cell contacts (adherence junctions, AJ) in all treatments ([Figure 8](#cells-08-01027-f008){ref-type="fig"}A, row 3), SE-Drug and SE-HIV promote the appearance of increased FA localization to membrane protrusions ([Figure 8](#cells-08-01027-f008){ref-type="fig"}B, row 3). Vinculin is known to be activated downstream of cell surface receptors and binds talin and F-actin to provide a physical link between the actin cytoskeleton and integrins \[[@B94-cells-08-01027]\]. Thus, we examined the colocalization of F-actin with vinculin. Increased areas of F-actin•Vinculin were observed at AJs in all treatments ([Figure 8](#cells-08-01027-f008){ref-type="fig"}A, row 4), with increased F-actin•Vinculin colocalization in AJs in cells treated with SE-Drug and SE-HIV ([Figure 8](#cells-08-01027-f008){ref-type="fig"}C,D). Moreover, a preponderance of SE-Drug and SE-HIV treated cells contain F-actin•Vinculin in areas of cell protrusions ([Figure 8](#cells-08-01027-f008){ref-type="fig"}B, row 4), but no significant difference was observed ([Figure 8](#cells-08-01027-f008){ref-type="fig"}E,F). Although the role of SE in cell-to-matrix and cell-to-cell adhesions is yet to be determined, the increased detection of vinculin at areas of cell-to-matrix and cell-to-cell contacts suggest possible SE-mediated recruitment of vinculin to FAs and AJs in monocytes. These findings suggest that the SE-induced adhesive and protrusive modules may be functionally linked by the actin network to facilitate mechanotransduction as well as to provide cues between cells.

4. Discussion {#sec4-cells-08-01027}
=============

In this study, we show that SEs are present in the semen of HIV-uninfected and HIV-infected participants independent of psychostimulants use. We also highlight the association of viral protein---RT and cocaine metabolite---benzoylecgonine with SE and show that SEs from study participants reprogrammed monocyte gene expression, morphometrics, and function.

Transcriptomics analysis of monocytes plated atop collagen and treated with SE from HIV−/+ and Drug−/+ groups showed that, in general, SE contain factors, such as COL16A1 and MMPs known to regulate cell adhesion \[[@B81-cells-08-01027],[@B82-cells-08-01027],[@B83-cells-08-01027]\] ([Figure 2](#cells-08-01027-f002){ref-type="fig"}F and [Figure 3](#cells-08-01027-f003){ref-type="fig"}C), cell chemotaxis ([Figure 4](#cells-08-01027-f004){ref-type="fig"}A), and metalloprotease activity ([Figure 4](#cells-08-01027-f004){ref-type="fig"}B). Furthermore, SE-Drug suppressed the expression of HUS1B, linked to the induction of cell death \[[@B85-cells-08-01027]\]. Amongst other observations was the result that SE-HIV suppressed the expression of TSC1, a protein known to maintain HIV in a latent state via the AKT-mTORC1 pathway \[[@B87-cells-08-01027]\]. These transcriptomic results support the observation that SE-Drug and SE-HIV promote monocyte adhesion, cytoskeletal reorganization, and chemotactic migration.

Categorization of DEGs in each treatment into GO and KEGG functional terms identified a common theme---FA as a potential SE-regulated function ([Table 8](#cells-08-01027-t008){ref-type="table"}). FAs are large protein complexes that physically connect the ECM to the cytoskeleton of the cells and are integral to cell adhesion, signaling, actin cytoskeleton dynamics, and cell migration while SE induced monocyte adhesion to collagen, HIV infection, and/or psychostimulant use resulted in the secretion of SE-Drug and SE-HIV that potentiated monocyte adhesion to collagen ([Figure 5](#cells-08-01027-f005){ref-type="fig"}). Indeed, HIV infection of lymphocytes and monocytes resulted in increased adhesion of the infected cells to vascular endothelium and ECM molecules \[[@B95-cells-08-01027]\], and treatment of monocytes with HIV Tat protein increased monocyte adhesion to endothelial monolayers \[[@B96-cells-08-01027]\].

Analyses of monocyte morphometrics and migration revealed that, in the presence of HIV infection and psychostimulant use, SE profoundly altered monocytes by increasing membrane ruffling and formation of filopodium-like structures. These changes resulted in variable modification of cell size and cell area by the different SEs; however, SE from HIV+Drug+ participants induced the most significant changes. These observations suggest that the ability of SE to regulate actin cytoskeleton dynamics, formation of membrane structures, FA, AJ, and localization of F-actin and vinculin to structures similar to the leading edge of migrating cells \[[@B97-cells-08-01027]\] and at cell--cell junctions depend on the microenvironment secreting the SE. On the basis of these observations, it is therefore possible that exosomes may modify FAs and AJs in response to changes in their microenvironment.

While FA bridges cells to ECM, AJ links neighboring cells and the actin--myosin cytoskeleton. These processes play a role in physiologic and pathologic signaling and cell migration and invasion during morphogenetics, tissue repair, and barrier disruption events \[[@B98-cells-08-01027],[@B99-cells-08-01027]\]. In the center of these cell-to-cell and cell-to-ECM interactions is the actin machinery \[[@B100-cells-08-01027]\], which we found profoundly colocalized with vinculin in FA and AJ ([Figure 8](#cells-08-01027-f008){ref-type="fig"}). Thus, elevated vinculin incorporation in the adhesion complexes may explain the observed enhanced firm adhesion of SE-Drug- and SE-HIV-treated monocytes to collagen and migration of monocytes to HIV secretome.

The components of FA and AJ include scaffolding molecules, GTPases, and enzymes (kinases, phosphatases, proteases, and lipases). We found that, in comparison to vehicle-treated cells, monocytes treated with SE \< SE-HIV \< SE-Drug, in this order, released bioactive enzymes with enhanced gelatinolytic and caseinolytic activities. Amongst the enzymes identified by their molecular weight and banding pattern were gelatinolytic MMP2 and MMP9 and caseinolytic MMP7. However, other enzymes regulated by SE are yet to be identified.

MMPs are vital to normal immune response to infection because they degrade the ECM for leukocyte migration and modulate the activity of cytokines, chemokines, and defensins. However, MMPs have been implicated in the upregulation of adhesion molecules \[[@B101-cells-08-01027]\] and in the immunopathology associated with tissue damage, metastasis, and microbial dissemination, such as bacterial meningitis, endotoxic shock, mycobacterial infection, and hepatitis B and HIV infection \[[@B102-cells-08-01027]\]. Our observation that SE-Drug and SE-HIV induced high levels of gelatinolytic and caseinolytic MMPs points to the potential that the use of psychostimulants and infection with HIV may change the function of SE. Indeed, it has been shown that HIV infection is associated with an altered production and secretion of MMPs which contribute to HIV-induced immunopathology, dysregulation of T-cell dynamics, leukocyte trafficking, and viral dissemination \[[@B72-cells-08-01027]\]. It is possible that the elevated MMP activity in HIV-infected cells may be related to HIV-associated immune activation, viral dissemination, and the development of HIV-associated diseases. In our studies, we observed that treatment of monocytes with SE from all clinical groups increased monocyte adhesion to collagen, with SE-Drug and SE-HIV producing the greatest increases ([Figure 5](#cells-08-01027-f005){ref-type="fig"}). Indeed, HIV infection of lymphocytes and monocytes results in increased adhesion of the infected cells to vascular endothelium and ECM molecules \[[@B103-cells-08-01027]\] and treatment of monocytes with HIV Tat protein increased monocyte adhesion to endothelial monolayers \[[@B104-cells-08-01027]\]. It has been shown that MMPs, especially MMP9, promotes the ability of HIV-infected mononuclear cells to traverse artificial basement membrane barriers \[[@B105-cells-08-01027],[@B106-cells-08-01027]\]. Similar to our observation of induction of MMP expression by SE, MMP9 is one of the immediate early genes expressed after HIV infection of monocyte/macrophage \[[@B107-cells-08-01027]\]. HIV proteins Tat and gp120 proteins upregulate MMP9 secretion from monocytes and T cells, while gp41-derived peptides stimulate MMP2 production \[[@B107-cells-08-01027],[@B108-cells-08-01027]\]. Furthermore, elevated levels of MMP9 has been reported in vivo from patients with HIV infection not receiving ART \[[@B109-cells-08-01027]\]. Thus, factors in SE in general and in SE-Drug and SE-HIV, in particular, may play important roles in orchestrating monocytes dynamics in HIV infection and substances abuse.

Finally, because of the potential role of MMP in HIV dissemination via transmigration of infected cells \[[@B110-cells-08-01027]\] and HIV-associated pathologies (brain injury/neuronal damage, HIV-associated dementia (HAD) \[[@B111-cells-08-01027],[@B112-cells-08-01027],[@B113-cells-08-01027]\], Kaposi's sarcoma (KS) \[[@B114-cells-08-01027],[@B115-cells-08-01027],[@B116-cells-08-01027]\], HIV-associated nephropathy (HIVAN) \[[@B117-cells-08-01027]\], and periodontal diseases \[[@B118-cells-08-01027],[@B119-cells-08-01027]\]), understanding the role of SE-Drug and SE-HIV in the induction of MMP enzyme activity may constitute a novel therapeutic approach for HIV infection.

Aside from the pathologic functions of monocytes, these cells perform systemic immune surveillance and maintenance of macrophage populations through constitutive migration from the bloodstream across the vascular endothelium. Thus, enhanced pathologic monocyte migration may promote disease while the consequence of losing constitutive migration may include defective cell-mediated immune responses. It remains to be determined whether alteration in monocyte morphometrics and motility induced by SE, SE-Drug, and SE-HIV will be pathologic or protective in primary monocytes. These interesting findings are limited by the possibility that HIV+Drug− and HIV+Drug+ SE may contain HIV particles because the semen samples were obtained before the advent of ART. Thus, HIV+ donors were almost certainly viremic. However, these limitations do not negate the findings of this study, since HIV particles and exosomes are naturally present in the semen of infected individuals. Hence, our findings highlight the possible events that may occur within individuals who are infected with HIV and use or do not use psychostimulants. Another caveat of this study is that the donors reported the use of multiple substances and alcohol. Thus, the observed effects may be due to one of the other substances or due to an interaction between different substances. Due to such complexities, well-controlled animal model studies are needed to determine drug-specific effects. Nevertheless, the presented data should pave the path for future works that study the effects of body fluids exosomes in the context of HIV infection and substance abuse.
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![Physical characterization of semen exosomes (SE) from different clinical groups: (**A**) Exosomes were isolated from semen specimens obtained from donors in different clinical groups---HIV−Drug−, HIV−Drug+, HIV+Drug−, and HIV+Drug+. Seminal plasma from different participants were pooled, and the exosomes were purified by size exclusion chromatography (SEC). Six pools of clarified seminal plasma (n = 2, 100 µL/donor) from each of the four clinical groups were purified by size exclusion chromatography (SEC), and fractions were collected. UV--Vis was used to monitor absorbance at 280 nm and turbidity at 600 nm, indicative of the presence of proteins and lipid-containing vesicles, respectively. The dotted curve and filled curve represent absorbance profiles at 280 nm (protein) and 600 nm (lipid), respectively. The gray vertical rectangle highlights exosome fraction. (**B**) Purified SE fractions were pooled, and total protein concentration was determined by Bradford assay. Nano Tracking Analysis (NTA) measurements of the different SE physical properties: (**C**) size distribution profile, (**D**) NTA-based particle mean size, (**E**) mean particle concentration, and (**F**) Mean zeta potential (ζ-potential, mV). (**G**) Negative-stain TEM images of purified SE from the four clinical groups: The insets correspond to zoomed areas indicated by the arrow. All scale bars = 100 nm. (**H**) TEM-based mean particle size from [Figure 1](#cells-08-01027-f001){ref-type="fig"}G determined with Image J. Assessment of HIV proteins: (**I**) HIV reverse transcriptase (RT) and (**J**) HIV p24. A total of 30 µg purified SE (\~6 × 10^9^ particles) from HIV+ groups (6 pools of 2 donors each) were tested in triplicate. An equivalent volume of PBS was used as the negative control. (**K**) Cocaine metabolite ELISA. A total of 30 µg purified SE (\~6 × 10^9^ particles) from Drug+ groups (6 pools of 2 donors each) were tested in triplicate. Equivalent volume of Phosphate Buffered Saline (PBS) was used as a negative control. The numbers in the graphs of [Figure 1](#cells-08-01027-f001){ref-type="fig"}B,D--F,H indicate mean values. Error bars indicate SEM of 6 biological replicates. For a two-group comparison, unpaired t-test with Welch's correction was used to determine the differences between the groups. For a four-group comparison, ordinary one-way ANOVA test (Dunnett's correction) was used to determine the differences between the SE groups as compared to HIV−Drug−. \* *p* \< 0.05, \*\* *p* \< 0.01, and ns, nonsignificant.](cells-08-01027-g001){#cells-08-01027-f001}

![Microarray analysis of monocytes (n = 15) treated with vehicle or SE from different clinical groups (triplicate per treatment): (**A**) Scatter plots of the different SE treatments compared to the vehicle control. Red and green dots correspond to the significantly up- and downregulated genes, respectively. Gray dots correspond to the unchanged genes. (**B**) Correlation matrix of all genes (21448) showing a differential pattern in monocyte gene expression. (**C**) Gene expression levels of dopamine receptors as determined by microarray analysis. Differences were not significant with the set filtration criteria of fold change (FC) \< −2 or FC \> 2 and *p*-value \< 0.05 (Benjamini and Hochberg correction for multiple observations). (**D**) Venn diagram analysis showing 30 differentially expressed genes (DEGs) common to all SE (HIV−Drug−, HIV−Drug+, HIV+Drug−, HIV+Drug+) treatments. The bold fonts in the Venn diagrams are the numbers of interest. (**E**) Hierarchical clustering heatmap showing the overall expression of the 30 SE-DEG. (**F**) Bar graph showing the fold change of each of the 30 SE-DEGs as compared to vehicle.](cells-08-01027-g002){#cells-08-01027-f002}

![Microarray analysis of SE-treated monocytes showing the effect of psychostimulant use and HIV infection on SE function: (**A**) Venn diagram showing 52 DEGs exclusive to the alterations induced by treatment with HIV−Drug+ and HIV+Drug+ SE (SE-Drug). (**B**) Hierarchical clustering heatmap showing the overall and direction of expression of the 52 SE-Drug. (**C**) Bar graph showing the fold change of the 52 SE-DEGs as compared to vehicle. (**D**--**F**) Similar analyses as in [Figure 3](#cells-08-01027-f003){ref-type="fig"}A--C showing 149 HIV exclusive DEGs in cells treated with HIV+Drug− and HIV+Drug+ SE (SE-HIV). The bold fonts in the Venn diagrams are the numbers of interest.](cells-08-01027-g003){#cells-08-01027-f003}

![Gene Ontology (GO) terms and PCR validation of selected DEGs: Biological processes and molecular functions of selected DEGs as determined by the overrepresentation analysis method from the web-based GEne SeT AnaLysis Toolkit. (**A**,**B**) SE, (**C**,**D**) SE-Drug, and (**E**,**F**) SE-HIV. Colored fonts are validated genes with blue as downregulated and red as upregulated genes. (**G**,**H**) RT-qPCR validation of selected DEGs in [Figure 4](#cells-08-01027-f004){ref-type="fig"}A--F (blue and red fonts). Ordinary one-way ANOVA test (Dunnett's correction) was used to determine the differences between the SE groups as compared to HIV−Drug−. Error bars indicate standard deviation of three technical replicates. \* *p* \< 0.05, and nonsignificant labels were not shown for clarity.](cells-08-01027-g004){#cells-08-01027-f004}

![Monocyte adhesion to collagen is increased by SE from HIV-infected participants with comorbid psychostimulant use: 10,000 cells were treated with vehicle PBS or 100 µg/mL (\~2 × 10^10^ particles/mL) SE from each clinical group and cultured atop collagen coated 96 well plate for 18 h in either complete media or serum free media. Subsequently, non-adhered cells were washed three times with PBS and adhered cells were stained with NucBlue. The entire well was imaged using LionHeart FX. The total number of adhered cells was determined using Gen5 Imaging software. Quantification of adherent monocytes in complete RPMI (**A**) and serum-free RPMI (**B**). Error bars indicate standard deviation of 4 independent wells per treatment. Analysis of monocyte viability by Live/Dead Stain (**C**) and Trypan Blue exclusion (**D**). Cell proliferation as determined by counting total live cells by Live/Dead Stain (**E**) or Trypan Blue stain (**F**). Error bars indicate standard deviation of three independent wells. Ordinary one-way ANOVA test (Dunnett's correction) was used to determine the differences induced by the different SE treatments as compare to vehicle. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.005, \*\*\*\* *p* \< 0.001, and ns, nonsignificant.](cells-08-01027-g005){#cells-08-01027-f005}

![Altered monocyte morphometrics following treatment with SE from participants who used psychostimulants and/or were infected with HIV: (**A**) 60× fluorescence images of U937 monocytes plated atop collagen, treated with vehicle and different SEs as indicated in the figure, and stained with phalloidin to visualize actin membrane structures. Cells treated with SE-Drug or SE-HIV had distinct changes in morphology and exhibited significant membrane ruffles and filopodia-like extensions. White arrows indicate areas of increased F-actin localization. Green arrows indicate filopodia-like structures. Yellow arrows indicate membrane ruffles. Scale bar = 30 µm. The membrane tracing was used to assess monocyte circularity. The white box corresponds to the enlarged area. Scale bar is 200 µm. (**B**) Scatterplot of cell size. (**C**) Scatterplot of cell area. (**D**) Ten times representative membrane tracing (with fill) images of vehicle and different SE treatments obtained with the Lionheart FX Gen5 software. (**E**) Scatter plot of cell circularity. Calculations were performed by Lionheart FX Gen5 software. Ordinary one-way ANOVA (Dunnett's correction) was used to determine the significance of SE treatments relative to vehicle. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.005, \*\*\*\* *p* \< 0.001, and ns, nonsignificant.](cells-08-01027-g006){#cells-08-01027-f006}

![Monocyte chemotaxis and secretion of matrix-modifying enzymes are potentiated by SE from HIV-infected and HIV-uninfected participants with co-occurring psychostimulant use: 500,000 U937 cells were treated with vehicle PBS or 100 µg/mL SE from the 4 clinical groups in serum-free media for 24 h before addition to the apical side of a chemotaxis chamber, containing 0% FBS (serum-free), 30% exosome-depleted FBS, or conditioned media from HIV-1 LAV-infected HeLa CD4+ cells (HIV secretome). The chambers were incubated for 20 h at 37 °C in a 5% CO~2~ incubator. The basal chamber cells were harvested and quantified by Trypan Blue hemocytometer counting. (**A**) Monocytes treated with the different SE were assessed for chemotaxis toward clarified supernatants collected from HIV-infected cells (HIV secretome), and the numbers of monocytes that migrated into HIV secretome in the basal compartment of the migration chamber are shown. (**B**) Viability of unmigrated cells in the apical chamber at the end of the experiment expressed as % of viable cells. (**C**) Representative (n = 3) gelatin Zymograph of conditioned media (secretome) from monocytes treated with the various SE prior to loading into migration chambers. The area within the square box is enlarged below to highlight active MMP9. (**D**) Image J quantification (total densitometry) of total gelatinolytic activity of each zymogram lane presented as the total area of proteolytic activity. Data represent the mean of triplicate experiments, and error bars are standard error of the mean. (**E**) Representative (n = 3) β-casein zymography of the same conditioned media used in gelatin zymography. Image J quantification (densitometry measurement) of [Figure 7](#cells-08-01027-f007){ref-type="fig"}F's (**F**) high molecular weight caseinolytic complex and (**G**) MMP7 activities of each zymogram lane presented as area of proteolytic activity. Experiments were repeated three times with similar trends. Ordinary one-way ANOVA (Dunnett's correction) test was used to determine the significance of different SE treatments relative to vehicle. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.005, \*\*\*\* *p* \< 0.001, and ns, nonsignificant.](cells-08-01027-g007){#cells-08-01027-f007}

![SE induced F-actin•Vinculin colocalization in monocytes. Representative 60× fluorescence images of U937 cells stained with phalloidin and vinculin to visualize (**A**) F-actin•Vinculin colocalization in adherence junctions. (**B**) F-actin•Vinculin colocalization in cell protrusions. Scale bar = 30 µm. Pearson correlation coefficient (PPC) and threshold overlap score (TOS, linear) plots corresponding to the images in [Figure 8](#cells-08-01027-f008){ref-type="fig"}A,B for comparison of F-actin•Vinculin colocalization in adherence junctions (**C**,**D**) and cell protrusions (**E**,**F**). Purple arrows indicate vinculin in AJs ([Figure 8](#cells-08-01027-f008){ref-type="fig"}A) or in areas of cell protrusion ([Figure 8](#cells-08-01027-f008){ref-type="fig"}B). Yellow arrows indicate F-actin•Vinculin complex in AJs ([Figure 8](#cells-08-01027-f008){ref-type="fig"}A) and areas of cell protrusions ([Figure 8](#cells-08-01027-f008){ref-type="fig"}B). Ordinary one-way ANOVA (Dunnett's correction) was used to assess statistical significance relative to vehicle. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.005, and ns, nonsignificant.](cells-08-01027-g008){#cells-08-01027-f008}

cells-08-01027-t001_Table 1

###### 

Description of psychostimulants and alcohol use by study participants.

  Specimen ID     Hash/Marijuana Since Last Visit   Ever Used Hash/Marijuana   Poppers Since Last Visit   Ever Used Poppers   Crack/Cocaine Use Since Last Visit   Ever Used Crack or Cocaine   Uppers Since Last Visit   Ever Used Uppers   Ecstasy Since Last Visit   Ever used Ecstasy   Heroin/Opiates Since Last Visit   Ever Used Heroin/Opiates   PCP Since Last Visit   Downers Since Last Visit   Ethyl Chloride Since Last Visit   Unspecified Drug Since Last Visit   N. of drinks/wk Since Last Visit   Alcohol Use Since last Visit (drinks/wk)   Drinking Since Last Visit
  --------------- --------------------------------- -------------------------- -------------------------- ------------------- ------------------------------------ ---------------------------- ------------------------- ------------------ -------------------------- ------------------- --------------------------------- -------------------------- ---------------------- -------------------------- --------------------------------- ----------------------------------- ---------------------------------- ------------------------------------------ ---------------------------
  **HIV−Drug−**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  A1              N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0.866                              1--3                                       Low/moderate
  A2              N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0.347                              1--3                                       Low/moderate
  A3              N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0                                  0                                          None
  A4              N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0                                  0                                          None
  A5              N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   2.25                               1--3                                       Low/moderate
  A6              N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0.245                              1--3                                       Low/moderate
  A7              N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0.245                              1--3                                       Low/moderate
  A8              N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   2.25                               1--3                                       Low/moderate
  A9              N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   5.25                               4--13                                      Low/moderate
  A10             N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0                                  0                                          None
  A11             N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0                                  0                                          None
  A12             N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   5.25                               4--13                                      Low/moderate
  A13             N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0                                  0                                          None
  A14             N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   2.25                               1--3                                       Low/moderate
  A15             N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   2.25                               1--3                                       Low/moderate
  A16             N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0.866                              1--3                                       Low/moderate
  **HIV−Drug+**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  B1              Y                                 Y                          Y                          Y                   Y                                    Y                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   24.5                               \>13                                       Moderate/heavy
  B2              Y                                 Y                          Y                          Y                   Y                                    Y                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   2.25                               1--3                                       Low/moderate
  B3              Y                                 Y                          N                          Y                   Y                                    Y                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   10.5                               4--13                                      Low/ moderate
  B4              Y                                 Y                          N                          Y                   Y                                    Y                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   12.25                              4--13                                      Moderate/heavy
  B5              Y                                 Y                          N                          Y                   Y                                    Y                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0.809                              1--3                                       Low/moderate
  B6              Y                                 Y                          N                          Y                   Y                                    Y                            Y                         Y                  N                          N                   N                                 N                          N                      N                          N                                 N                                   12.25                              4--13                                      Moderate/heavy
  B7              Y                                 Y                          N                          Y                   Y                                    Y                            Y                         Y                  N                          N                   N                                 N                          N                      Y                          N                                 N                                   5.25                               4--13                                      Moderate/heavy
  B8              Y                                 Y                          N                          Y                   Y                                    Y                            N                         Y                  N                          N                   Y                                 Y                          N                      Y                          N                                 N                                   5.25                               4--13                                      Moderate/heavy
  B9              Y                                 Y                          N                          Y                   Y                                    Y                            N                         Y                  N                          N                   N                                 N                          N                      N                          N                                 N                                   10.5                               4--13                                      Low/moderate
  B10             Y                                 Y                          Y                          Y                   Y                                    Y                            N                         Y                  N                          N                   N                                 N                          N                      Y                          N                                 N                                   12.25                              4--13                                      Moderate/heavy
  B11             N                                 Y                          N                          Y                   Y                                    Y                            N                         Y                  N                          N                   N                                 N                          N                      N                          N                                 N                                   2.25                               1--3                                       Low/moderate
  B12             Y                                 Y                          N                          Y                   Y                                    Y                            N                         Y                  N                          Y                   N                                 N                          N                      N                          N                                 N                                   2.02                               1--3                                       Moderate/heavy
  B13             Y                                 Y                          N                          Y                   Y                                    Y                            N                         N                  N                          N                   N                                 Y                          N                      N                          N                                 N                                   5.25                               4--13                                      Low/moderate
  B14             Y                                 Y                          N                          Y                   Y                                    Y                            N                         N                  N                          N                   N                                 Y                          N                      N                          N                                 N                                   12                                 4--13                                      Binge
  B15             Y                                 Y                          Y                          Y                   Y                                    Y                            Y                         Y                  Y                          Y                   N                                 N                          N                      Y                          Y                                 N                                   56                                 \>13                                       Binge
  B16             Y                                 Y                          N                          Y                   Y                                    Y                            N                         N                  N                          Y                   N                                 N                          N                      N                          N                                 N                                   0.866                              1--3                                       Low/moderate
  **HIV+Drug−**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  C1              N                                 Y                          N                          Y                   N                                    N                            N                         Y                  N                          N                   N                                 N                          N                      N                          N                                 N                                   5.25                               4--13                                      Low/moderate
  C2              N                                 Y                          N                          Y                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   5.25                               4--13                                      Low/moderate
  C3              N                                 Y                          N                          Y                   N                                    Y                            N                         Y                  N                          Y                   N                                 N                          N                      N                          N                                 N                                   2.25                               1--3                                       Low/moderate
  C4              N                                 N                          N                          Y                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0                                  0                                          None
  C5              N                                 Y                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0.866                              1--3                                       Low/moderate
  C6              N                                 Y                          N                          Y                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   2.25                               1--3                                       Low/moderate
  C7              N                                 Y                          N                          Y                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   5.25                               4--13                                      Low/moderate
  C8              N                                 Y                          N                          Y                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0                                  0                                          None
  C9              N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0                                  0                                          None
  C10             N                                 Y                          N                          Y                   N                                    Y                            N                         Y                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0                                  0                                          None
  C11             N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0                                  0                                          None
  C12             N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0.866                              1--3                                       Low/moderate
  C13             N                                 N                          N                          N                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   5.25                               4--13                                      Low/moderate
  C14             N                                 Y                          N                          Y                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0.347                              1--3                                       Low/moderate
  C15             N                                 Y                          N                          Y                   N                                    Y                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0                                  0                                          None
  C16             N                                 Y                          N                          Y                   N                                    N                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   0                                  0                                          None
  **HIV+Drug+**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  D1              Y                                 Y                          Y                          Y                   Y                                    Y                            Y                         Y                  Y                          Y                   N                                 N                          N                      N                          Y                                 N                                   12.25                              4--13                                      Moderate/heavy
  D2              Y                                 Y                          N                          Y                   Y                                    Y                            N                         Y                  Y                          Y                   N                                 Y                          N                      N                          N                                 Y                                   10.5                               4--13                                      Low/moderate
  D3              Y                                 Y                          Y                          Y                   Y                                    Y                            N                         Y                  N                          Y                   N                                 N                          N                      N                          N                                 N                                   24.5                               \>13                                       Moderate/heavy
  D4              Y                                 Y                          Y                          Y                   Y                                    Y                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   24.5                               \>13                                       Moderate/heavy
  D5              Y                                 Y                          N                          Y                   Y                                    Y                            N                         Y                  N                          Y                   N                                 N                          N                      N                          N                                 N                                   24.5                               \>13                                       Moderate/heavy
  D6              Y                                 Y                          Y                          Y                   Y                                    Y                            Y                         Y                  Y                          Y                   N                                 N                          N                      Y                          Y                                 N                                   24.5                               \>13                                       Moderate/heavy
  D7              Y                                 Y                          N                          Y                   Y                                    Y                            N                         Y                  N                          N                   N                                 N                          N                      N                          N                                 N                                   2.25                               1--3                                       Low/moderate
  D8              Y                                 Y                          Y                          Y                   Y                                    Y                            N                         Y                  N                          Y                   N                                 N                          N                      N                          N                                 N                                   2.25                               1--3                                       Low/moderate
  D9              Y                                 Y                          Y                          Y                   Y                                    Y                            N                         N                  N                          N                   N                                 N                          N                      N                          N                                 N                                   5.25                               4--13                                      Low/moderate
  D10             N                                 Y                          N                          Y                   Y                                    Y                            N                         Y                  N                          Y                   N                                 N                          Y                      N                          N                                 N                                   38.5                               \>13                                       Binge
  D11             Y                                 Y                          Y                          Y                   Y                                    Y                            Y                         Y                  N                          N                   N                                 N                          Y                      Y                          N                                 N                                   10.5                               4--13                                      Low/moderate
  D12             Y                                 Y                          Y                          Y                   Y                                    Y                            Y                         Y                  N                          Y                   N                                 N                          N                      N                          Y                                 N                                   56                                 \>13                                       Binge
  D13             Y                                 Y                          N                          Y                   Y                                    Y                            N                         Y                  N                          N                   N                                 Y                          Y                      N                          N                                 N                                   12.25                              4--13                                      Moderate/heavy
  D14             Y                                 Y                          Y                          Y                   Y                                    Y                            Y                         Y                  N                          N                   N                                 N                          N                      N                          N                                 N                                   5.25                               4--13                                      Moderate/heavy
  D15             Y                                 Y                          Y                          Y                   Y                                    Y                            N                         Y                  N                          Y                   N                                 Y                          N                      N                          N                                 N                                   12                                 4--13                                      Binge
  D16             Y                                 Y                          N                          N                   Y                                    Y                            Y                         Y                  N                          N                   N                                 N                          Y                      N                          N                                 N                                   2.02                               1--3                                       Moderate/heavy

Y = Yes; N = No.

cells-08-01027-t002_Table 2

###### 

Primer sequences.

  Gene Symbol   Forward Primer            Reverse Primer
  ------------- ------------------------- ------------------------
  PTPRC         AATCTCCCTAGGCAGAGGCA      CCTCCCTCATGTGGCCAATT
  ADGRG3        AGCGTATCACATGGCGAGAG      CCTGAGGGGAGGAGATTGGA
  RELB          GATGGAGTCTCGCTCTGTCG      ATCCCAGCACTTTGAGAGGC
  IL1B          ATGATGGCTTATTACAGTGGCAA   GTCGGAGATTCGTAGCTGGA
  CD86          TATGGGCCGCACAAGTTTT       TCCTGTGGGCTTTTTGTGAT
  MMP19         GAGGACTGGAGGCTGGAGTA      TGAAGGAGGGAGAGGGATGG
  MMP9          TGAGGTGGTAGGATCGCTGA      ATGCCAGATCTCTGACCCCT
  MMP1          AGTGGCCCAGTGGTTGAAAA      CCACATCAGGCAC
  ELF1          TCCCAGCTATTCAGGAGGCT      CCCAAAGTTGCAGTGCAGTC
  USP3          ATCCTCCCACCTCAGTCTCC      AGGCTGAGGTGGAGGATCAT
  BBS4          GATGGAGTCTCGCTCTGTCG      AAATTAGCCGGGAGTGGTGG
  TSC1          CTTGAGCTGGTGAGTGAGCA      GCGCTTGGCACTATTACTGC
  EXOC4         CTGCCTCTGTACACGTGTGT      CGAGACAGCGAGACTCCATC
  FGFR1         CAAAGGGGTGTGCGTTTCAG      TGGAGATGGGGTGGGAGTAG
  TFAP4         CAGCGATTTCCGAATGCCTG      CAGCCTGGGCAACATAGTGA
  ELK3          GTTTGTGACAGGCAGCACTG      CCTGGGGAGAGAAGGGATCA
  FOSB          TTTTCTCCTCCGCCTGTGTC      TCACACTCTCACACTCGCAC
  FOS           GCCCATTCCATCCCAACTCA      TGCCATCACCTCCATTCACC
  FOXJ2         TAGAGGAGGGTGGGGTGATG      AGCCAGGCTCATAGTCAGGA
  ERG           GACAACACAGCCAGCACTTG      CAGTTGTGCAAGTGTTCCCG
  CREB1         TGCTGCACACATCATCCCAT      TAGATGGAGCTGGAGGCCTT
  VTN           TCCCTGCCCATAGCTACAGT      AGGATCTCCCAGCATGAGGT
  ATXN2L        GAGGGATGACTGGGAGGACT      CTAGTCCCTGCCCTAGGTGT
  EGR1          CAGACCAGAAGCCCTTCCAG      TGGGTTTGATGAGCTGGGAC
  YARS          CCTGTGTAAAGGCCCGGATT      CACAAACACGTGCTCACCAG
  CD9           CCCACAAGGATGAGTTGATT      CAGCTTGTTGTAGGTGTCCTTG
  POGZ          GTGCAGGACGTTGTCAACAC      GCCTCTCAAAGTGCTGGGAT

cells-08-01027-t003_Table 3

###### 

Summary of the DEG in the four clinical groups (n = 3) as compared to vehicle ^1^.

              Genes Passed Filter Criteria ^1^   \% of Total Genes ^2^   Upregulated   Downregulated         
  ----------- ---------------------------------- ----------------------- ------------- --------------- ----- -------
  HIV−Drug−   293                                1.37                    177           60.41           116   39.59
  HIV−Drug+   497                                2.32                    92            18.51           405   81.49
  HIV+Drug−   641                                2.99                    179           27.93           462   72.07
  HIV+Drug+   647                                3.02                    240           37.09           407   62.91

^1^ Filtration criteria FC \< −2 or FC \> 2 and *p*-value \< 0.05 (Benjamini and Hochberg correction for multiple observations); ^2^ Total number of genes = 21448.

cells-08-01027-t004_Table 4

###### 

Top 10 biological process GO terms from Webgestalt analysis ^1^.

                     Gene Set                                               Description                        \# of Genes in Pathway   DEG in Pathway   Enrichment Score   *p*-Value
  ------------------ ------------------------------------------------------ ---------------------------------- ------------------------ ---------------- ------------------ ---------------
  **SE-DEGs**        GO:0036230                                             granulocyte activation             500                      8                8.775              2.01 × 10^−6^
  GO:0060326         cell chemotaxis                                        289                                6                        11.386           1.10 × 10^−5^      
  GO:0002446         neutrophil mediated immunity                           496                                7                        7.740            2.25 × 10^−5^      
  GO:0097305         response to alcohol                                    231                                5                        11.870           5.40 × 10^−5^      
  GO:0050900         leukocyte migration                                    419                                6                        7.853            8.85 × 10^−5^      
  GO:0032103         positive regulation of response to external stimulus   293                                5                        9.358            1.66 × 10^−4^      
  GO:0001525         angiogenesis                                           487                                6                        6.757            2.02 × 10^−4^      
  GO:2000147         positive regulation of cell motility                   493                                6                        6.674            2.15 × 10^−4^      
  GO:0002521         leukocyte differentiation                              496                                6                        6.634            2.23 × 10^−4^      
  GO:0009636         response to toxic substance                            499                                6                        6.594            2.30 × 10^−4^      
  **SE-Drug DEGs**   GO:1902115                                             regulation of organelle assembly   209                      4                8.856              1.02 × 10^−3^
  GO:0140029         exocytic process                                       84                                 2                        11.017           1.41 × 10^−2^      
  GO:0043254         regulation of protein complex assembly                 447                                4                        4.141            1.51 × 10^−2^      
  GO:0071826         ribonucleoprotein complex subunit organization         245                                3                        5.666            1.56 × 10^−2^      
  GO:0006289         nucleotide-excision repair                             110                                2                        8.413            2.35 × 10^−2^      
  GO:0006520         cellular amino acid metabolic process                  318                                3                        4.365            3.07 × 10^−2^      
  GO:0031023         microtubule organizing center organization             134                                2                        6.906            3.38 × 10^−2^      
  GO:0071800         podosome assembly                                      20                                 1                        23.136           4.24 × 10^−2^      
  GO:0051383         kinetochore organization                               21                                 1                        22.034           4.44 × 10^−2^      
  **SE-HIV DEGs**    GO:0045576                                             mast cell activation               61                       5                10.646             1.05 × 10^−4^
  GO:0071824         protein-DNA complex subunit organization               242                                9                        4.830            1.05 × 10^−4^      
  GO:0002764         immune response-regulating signaling pathway           485                                12                       3.214            3.55 × 10^−4^      
  GO:0002285         lymphocyte activation involved in immune response      172                                7                        5.286            3.66 × 10^−4^      
  GO:0036230         granulocyte activation                                 500                                12                       3.117            4.67 × 10^−4^      
  GO:0006959         humoral immune response                                242                                8                        4.294            5.63 × 10^−4^      
  GO:0002526         acute inflammatory response                            154                                6                        5.060            1.22 × 10^−3^      
  GO:0001525         angiogenesis                                           487                                11                       2.934            1.33 × 10^−3^      
  GO:0002683         negative regulation of immune system process           416                                10                       3.122            1.39 × 10^−3^      

^1^ Parameters for the enrichment analysis were as follows: Enrichment method: Over-representation Analysis (ORA), organism: hsapiens, enrichment categories: geneontology_Biological_Process_noRedundant, minimum number of IDs in the category: 5, maximum number of IDs in the category: 2000, False discovery rate (FDR) method: Benjamini and Hochberg, significance level: Top 10.
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###### 

Top 10 molecular function GO terms from Webgestalt analysis ^1^.

                     Gene Set                                                                                  Description                           \# of Genes in Pathway   DEG in Pathway   Enrichment Score   *p*-Value
  ------------------ ----------------------------------------------------------------------------------------- ------------------------------------- ------------------------ ---------------- ------------------ ---------------
  **SE−DEGs**        GO:1990841                                                                                promoter-specific chromatin binding   46                       2                26.787             2.48 × 10^−3^
  GO:0019199         transmembrane receptor protein kinase activity                                            81                                    2                        15.212           7.51 × 10^−3^      
  GO:0019838         growth factor binding                                                                     138                                   2                        8.929            2.07 × 10^−2^      
  GO:0001653         peptide receptor activity                                                                 149                                   2                        8.270            2.39 × 10^−2^      
  GO:0001228         DNA-binding transcription activator activity, RNA polymerase II-specific                  444                                   3                        4.163            3.36 × 10^−2^      
  GO:0008237         metallopeptidase activity                                                                 185                                   2                        6.661            3.57 × 10^−2^      
  GO:1901567         fatty acid derivative binding                                                             27                                    1                        22.819           4.30 × 10^−2^      
  GO:0017171         serine hydrolase activity                                                                 208                                   2                        5.924            4.41 × 10^−2^      
  GO:0043177         organic acid binding                                                                      212                                   2                        5.812            4.57 × 10^−2^      
  GO:0035035         histone acetyltransferase binding                                                         29                                    1                        21.245           4.61 × 10^−2^      
  **SE−Drug DEGs**   GO:0140098                                                                                catalytic activity, acting on RNA     350                      3                3.912              4.02 × 10^−2^
  GO:0016701         oxidoreductase activity, acting on single donors with incorporation of molecular oxygen   28                                    1                        16.299           5.96 × 10^−2^      
  GO:0060090         molecular adaptor activity                                                                194                                   2                        4.705            6.69 × 10^−2^      
  GO:0050839         cell adhesion molecule binding                                                            478                                   3                        2.864            8.53 × 10^−2^      
  GO:1990841         promoter-specific chromatin binding                                                       46                                    1                        9.921            9.61 × 10^−2^      
  GO:0097110         scaffold protein binding                                                                  58                                    1                        7.868            1.20 × 10^−1^      
  GO:0000049         tRNA binding                                                                              59                                    1                        7.735            1.22 × 10^−1^      
  GO:0070491         repressing transcription factor binding                                                   73                                    1                        6.252            1.48 × 10^−1^      
  GO:0015631         tubulin binding                                                                           321                                   2                        2.843            1.55 × 10^−1^      
  **SE−HIV DEGs**    GO:0019865                                                                                immunoglobulin binding                23                       3                16.235             7.93 × 10^−4^
  GO:0001228         DNA−binding transcription activator activity, RNA polymerase II−specific                  444                                   11                       3.084            8.52 × 10^−4^      
  GO:0016209         antioxidant activity                                                                      84                                    4                        5.927            4.63 × 10^−3^      
  GO:0070888         E-box binding                                                                             50                                    3                        7.468            7.50 × 10^−3^      
  GO:0016684         oxidoreductase activity, acting on peroxide as acceptor                                   55                                    3                        6.789            9.76 × 10^−3^      
  GO:0001227         DNA-binding transcription repressor activity, RNA polymerase II−specific                  267                                   6                        2.797            2.05 × 10^−2^      
  GO:0060589         nucleoside-triphosphatase regulator activity                                              348                                   7                        2.504            2.19 × 10^−2^      
  GO:0005496         steroid binding                                                                           92                                    3                        4.059            3.78 × 10^−2^      
  GO:0015026         coreceptor activity                                                                       43                                    2                        5.789            4.66 × 10^−2^      

^1^ Parameters for the enrichment analysis were as follows: Enrichment method: ORA, organism: hsapiens, enrichment categories: geneontology_Molecular_Function_noRedundant, minimum number of IDs in the category: 5, maximum number of IDs in the category: 2000, FDR method: Benjamini and Hochberg, significance level: Top 10.
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###### 

Top 10 cellular component GO terms from Webgestalt analysis ^1^.

                     Gene Set                             Description                  \# of Genes in Pathway   DEG in Pathway   Enrichment Score   *p*-Value
  ------------------ ------------------------------------ ---------------------------- ------------------------ ---------------- ------------------ ---------------
  **SE−DEGs**        GO:0030667                           secretory granule membrane   293                      5                9.554              1.26 × 10^−4^
  GO:0042581         specific granule                     160                          3                        10.498           2.69 × 10^−3^      
  GO:0070820         tertiary granule                     163                          3                        10.305           2.84 × 10^−3^      
  GO:0101002         ficolin-1-rich granule               183                          3                        9.179            3.93 × 10^−3^      
  GO:0031012         extracellular matrix                 496                          4                        4.515            1.02 × 10^−2^      
  GO:0031904         endosome lumen                       36                           1                        15.552           6.24 × 10^−2^      
  GO:1903293         phosphatase complex                  47                           1                        11.913           8.08 × 10^−2^      
  GO:0005788         endoplasmic reticulum lumen          306                          2                        3.659            1.02 × 10^−1^      
  GO:0001533         cornified envelope                   65                           1                        8.614            1.10 × 10^−1^      
  GO:0005766         primary lysosome                     155                          1                        3.612            2.44 × 10^−1^      
  **SE−Drug DEGs**   GO:0030496                           midbody                      171                      3                8.419              5.10 × 10^−3^
  GO:0005681         spliceosomal complex                 176                          3                        8.180            5.52 × 10^−3^      
  GO:0090734         site of DNA damage                   66                           2                        14.543           8.19 × 10^−3^      
  GO:0099023         tethering complex                    67                           2                        14.326           8.43 × 10^−3^      
  GO:0016607         nuclear speck                        383                          3                        3.759            4.36 × 10^−2^      
  GO:0044450         microtubule organizing center part   178                          2                        5.392            5.23 × 10^−2^      
  GO:0035770         ribonucleoprotein granule            214                          2                        4.485            7.24 × 10^−2^      
  GO:0005770         late endosome                        242                          2                        3.966            8.95 × 10^−2^      
  GO:0001917         photoreceptor inner segment          49                           1                        9.794            9.74 × 10^−2^      
  **SE−HIV DEGs**    GO:0030667                           secretory granule membrane   293                      8                3.127              3.98 × 10^−3^
  GO:0005766         primary lysosome                     155                          5                        3.694            1.14 × 10^−2^      
  GO:0042629         mast cell granule                    22                           2                        10.411           1.55 × 10^−2^      
  GO:0000790         nuclear chromatin                    341                          7                        2.351            2.92 × 10^−2^      
  GO:0016605         PML body                             99                           3                        3.470            5.55 × 10^−2^      
  GO:0005801         cis-Golgi network                    60                           2                        3.817            9.64 × 10^−2^      
  GO:0045177         apical part of cell                  375                          6                        1.832            1.09 × 10^−1^      
  GO:0034399         nuclear periphery                    133                          3                        2.583            1.10 × 10^−1^      
  GO:0042383         sarcolemma                           134                          3                        2.564            1.12 × 10^−1^      

^1^ Parameters for the enrichment analysis were as follows: Enrichment method: ORA, organism: hsapiens, enrichment categories: geneontology_Cellular_Component_noRedundant, minimum number of IDs in the category: 5, maximum number of IDs in the category: 2000, FDR method: Benjamini and Hochberg, significance level: Top 10.
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###### 

Top 10 KEGG pathways from Webgestalt analysis ^1^.

                     Gene Set                                              Description                               \# of Genes in Pathway   DEG in Pathway   Enrichment Score   *p*-Value
  ------------------ ----------------------------------------------------- ----------------------------------------- ------------------------ ---------------- ------------------ ---------------
  **SE−DEGs**        hsa04657                                              IL-17 signaling pathway                   93                       4                17.374             6.69 × 10^−5^
  hsa05150           Staphylococcus aureus infection                       56                                        3                        21.640           3.25 × 10^−4^      
  hsa05323           Rheumatoid arthritis                                  90                                        3                        13.465           1.31 × 10^−3^      
  hsa04928           Parathyroid hormone synthesis, secretion and action   106                                       3                        11.432           2.10 × 10^−3^      
  hsa04080           Neuroactive ligand-receptor interaction               277                                       4                        5.833            4.13 × 10^−3^      
  hsa05031           Amphetamine addiction                                 68                                        2                        11.881           1.20 × 10^−2^      
  hsa04917           Prolactin signaling pathway                           70                                        2                        11.541           1.27 × 10^−2^      
  hsa04610           Complement and coagulation cascades                   79                                        2                        10.226           1.59 × 10^−2^      
  hsa05132           Salmonella infection                                  86                                        2                        9.394            1.87 × 10^−2^      
  hsa05142           Chagas disease (American trypanosomiasis)             102                                       2                        7.920            2.58 × 10^−2^      
  **SE−Drug DEGs**   hsa04914                                              Progesterone−mediated oocyte maturation   99                       2                9.181              1.95 × 10^−2^
  hsa04931           Insulin resistance                                    107                                       2                        8.494            2.25 × 10^−2^      
  hsa04114           Oocyte meiosis                                        124                                       2                        7.330            2.96 × 10^−2^      
  hsa03040           Spliceosome                                           133                                       2                        6.834            3.37 × 10^−2^      
  hsa04910           Insulin signaling pathway                             137                                       2                        6.634            3.56 × 10^−2^      
  hsa04150           mTOR signaling pathway                                151                                       2                        6.019            4.25 × 10^−2^      
  hsa01523           Antifolate resistance                                 31                                        1                        14.659           6.61 × 10^−2^      
  hsa00260           Glycine, serine and threonine metabolism              40                                        1                        11.361           8.46 × 10^−2^      
  hsa00970           Aminoacyl-tRNA biosynthesis                           44                                        1                        10.328           9.26 × 10^−2^      
  **SE−HIV DEGs**    hsa05150                                              Staphylococcus aureus infection           56                       5                9.836              1.41 × 10^−4^
  hsa04380           Osteoclast differentiation                            128                                       5                        4.303            5.93 × 10^−3^      
  hsa05202           Transcriptional misregulation in cancer               186                                       6                        3.554            6.58 × 10^−3^      
  hsa05322           Systemic lupus erythematosus                          133                                       5                        4.142            6.95 × 10^−3^      
  hsa00515           Mannose type O-glycan biosynthesis                    23                                        2                        9.580            1.82 × 10^−2^      
  hsa04115           p53 signaling pathway                                 72                                        3                        4.590            2.73 × 10^−2^      
  hsa05166           Human T-cell leukemia virus 1 infection               255                                       6                        2.592            2.75 × 10^−2^      
  hsa00410           Beta-Alanine metabolism                               31                                        2                        7.108            3.19 × 10^−2^      
  hsa04710           Circadian rhythm                                      31                                        2                        7.108            3.19 × 10^−2^      

^1^ Parameters for the enrichment analysis were as follows: Enrichment method: ORA, organism: hsapiens, enrichment categories: pathway_KEGG, minimum number of IDs in the category: 5, maximum number of IDs in the category: 2000, FDR method: Benjamini and Hochberg, significance level: Top 10.
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###### 

Top 10 KEGG pathways by count as determined by Transcriptome Analysis Console (TAC) software ^1^.

                                                                  Pathway                                       \#Total   \#Up   \#Down   Significance   *p*-Value
  --------------------------------------------------------------- --------------------------------------------- --------- ------ -------- -------------- -----------
  **HIV-Drug-**                                                   PI3K-Akt Signaling Pathway                    20        13     7        0              1
  **Focal Adhesion**-PI3K-Akt-mTOR-signaling pathway              20                                            13        7      0.21     0.62234        
  VEGFA-VEGFR2 Signaling Pathway                                  20                                            12        8      0.9      0.127165       
  Nuclear Receptors Meta-Pathway                                  20                                            11        9      0.09     0.811647       
  Regulation of toll-like receptor signaling pathway              19                                            10        9      2.84     0.001437       
  MAPK Signaling Pathway                                          18                                            9         9      0.47     0.3394         
  miR-targeted genes in muscle cell---TarBase                     17                                            7         10     0.93     0.116256       
  miR-targeted genes in lymphocytes---TarBase                     17                                            7         10     2        0.009973       
  Toll-like Receptor Signaling Pathway                            15                                            9         6      2.96     0.001086       
  Olfactory receptor activity                                     15                                            12        3      1        0.100786       
  **HIV-Drug+**                                                   PI3K-Akt Signaling Pathway                    35        8      27       0.11           0.783262
  miR-targeted genes in lymphocytes---TarBase                     34                                            3         31     1.89     0.012864       
  miR-targeted genes in muscle cell---TarBase                     32                                            3         29     0.87     0.136266       
  **Focal Adhesion**-PI3K-Akt-mTOR-signaling pathway              30                                            8         22     0.03     0.922794       
  Olfactory receptor activity                                     24                                            8         16     1.82     0.015221       
  Nuclear Receptors Meta-Pathway                                  24                                            6         18     0.8      0.157659       
  VEGFA-VEGFR2 Signaling Pathway                                  22                                            7         15     0.08     0.827347       
  miR-targeted genes in epithelium---TarBase                      22                                            3         19     1.72     0.01896        
  Genes related to primary cilium development (based on CRISPR)   21                                            1         20     2.73     0.001861       
  Ciliary landscape                                               21                                            0         21     0        1              
  **HIV+Drug-**                                                   miR-targeted genes in lymphocytes---TarBase   46        8      38       0.87           0.134124
  Nuclear Receptors Meta-Pathway                                  41                                            17        24     0.43     0.372732       
  PI3K-Akt Signaling Pathway                                      40                                            14        26     0.14     0.728467       
  miR-targeted genes in muscle cell---TarBase                     38                                            8         30     0.74     0.183176       
  MAPK Signaling Pathway                                          37                                            11        26     1.18     0.065447       
  **Focal Adhesion**-PI3K-Akt-mTOR-signaling pathway              35                                            15        20     0.11     0.783054       
  VEGFA-VEGFR2 Signaling Pathway                                  35                                            12        23     1.01     0.097823       
  miR-targeted genes in epithelium---TarBase                      29                                            7         22     1.06     0.087395       
  Breast cancer pathway                                           26                                            8         18     1.54     0.029057       
  Circadian rhythm related genes                                  26                                            7         19     0.3      0.50212        
  **HIV+Drug+**                                                   Nuclear Receptors Meta-Pathway                43        29     14       0.67           0.211976
  PI3K-Akt Signaling Pathway                                      42                                            17        25     0.31     0.487261       
  miR-targeted genes in lymphocytes---TarBase                     42                                            9         33     1.42     0.038159       
  **Focal Adhesion**-PI3K-Akt-mTOR-signaling pathway              37                                            16        21     0.28     0.520416       
  VEGFA-VEGFR2 Signaling Pathway                                  36                                            18        18     1.2      0.062498       
  miR-targeted genes in muscle cell---TarBase                     34                                            10        24     1.38     0.041842       
  miR-targeted genes in epithelium---TarBase                      27                                            8         19     1.48     0.032898       
  MAPK Signaling Pathway                                          26                                            11        15     0.08     0.838897       
  TGF-beta Signaling Pathway                                      25                                            10        15     1.9      0.012623       
  Ciliary landscape                                               23                                            8         15     0.04     0.913439       

^1^ Gene expression parameters were as follows: Gene-level fold change \< −2 or \> 2; gene-level *p*-value \< 0.05, gene-level FDR \< 0.05, ANOVA statistical analysis with eBayes correction. The Pos/Neg Area Under the Curve (AUC) threshold was set to 0.7. Gene-level Signal Space Transformation-Robust Multi-Chip Analysis (SST-RMA) method was used for summarization.
